A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
This is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics
and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or
mutated advanced malignant solid tumor subjects.